SuperworthANI Pharmaceuticals EPS ANIP
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $4.70
- Latest quarter, Q2 FY26
- $1.05
- +192% on a year earlier
- Fiscal year 2025
- $3.42
ANI Pharmaceuticals' earnings per share was $4.70 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $1.05, up 192% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $3.42 | n/a |
| FY2024 | −$1.14 | −236% |
| FY2023 | $0.84 | n/a |
| FY2022 | −$3.04 | n/a |
| FY2021 | −$3.25 | n/a |
| FY2020 | −$1.88 | −492% |
| FY2019 | $0.48 | −63% |
| FY2018 | $1.30 | n/a |
| FY2017 | −$0.10 | −129% |
| FY2016 | $0.35 | −74% |
| FY2015 | $1.33 | −47% |
| FY2014 | $2.53 | n/a |
| FY2013 | −$6.08 | n/a |
| FY2012 | −$2944.10 | n/a |
| FY2011 | −$19.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.05 | +192% | $4.70 | |
| Q1 FY26 | $1.28 | +86% | $4.01 | |
| Q4 FY25 | $1.24 | n/a | $3.42 | |
| Q3 FY25 | $1.13 | n/a | $1.63 | |
| Q2 FY25 | $0.36 | n/a | −$0.77 | |
| Q1 FY25 | $0.69 | −16% | −$1.27 | |
| Q4 FY24 | −$0.55 | −1475% | −$1.14 | |
| Q3 FY24 | −$1.27 | −382% | −$0.55 | |
| Q2 FY24 | −$0.14 | −148% | $1.17 | |
| Q1 FY24 | $0.82 | +1267% | $1.60 | |
| Q4 FY23 | $0.04 | n/a | $0.84 | |
| Q3 FY23 | $0.45 | n/a | $0.52 |
Against its peers
Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ABUSArbutus Biopharma | $0.78 | |
| OGNOrganon | $0.77 | −71% a year |
| Peer median | $2.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on ANI Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.